Results for the Third Quarter 2017

Currency neutral growth of own products is 12.5%. Flow probe sales negatively impacted with MNOK 2.2, however, production of flow probe capacity is improving and backorder is reduced from 500 to 250 probes. Another strong…

Read more

Results for the Second Quarter 2017

Currency neutral growth of own products was 4.7 % and was negatively impacted by delayed flow probe deliveries amounting to MNOK 5.5. Currency neutral growth of own products was 10.7 % for the 1st half.…

Read more

Medistim has received clearance for sale of MiraQ™ in China

MiraQ™ represents Medistim's most advanced system for ultrasonic surgical guidance and quality assessment used intraoperatively during coronary artery bypass grafting (CABG) as well as vascular and transplant surgery. The system combines state-of-the-art transit time blood…

Read more

Results for the First Quarter 2017

Sales in the first quarter amounted to MNOK 74.4 (MNOK 65.5), a 13.5 % growth. Currency neutral growth of own products was 20.3 %. Sales from the US increases with 9.6 % in USD. In…

Read more

Annual Report 2016

Sales for the group in 2016 ended at 268.1 MNOK (251.4 MNOK), a 6.6 % growth. Download full report here: Annual Report Medistim 2016

Read more

Results for the Fourth Quarter 2016

Currency neutral sales of own products decreased with 3 MNOK or 5.7 % due in part to a back order situation on TTFM flow probes. Currency neutral sales of own products increased with 9.5 %…

Read more